A study has revealed why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and identifies a new ...

A team of Newcastle University experts have discovered a new way to treat cancers that have proved hard to tackle previously.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a biomarkers in kidney cancer session. Dr. David McDermott discussed the ongoing ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

New phase 1 findings highlight promise of first-in-class bispecific antibody fusion for advanced colorectal cancer.

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...